Table I.
Serum levels of AMY, ALT and AST in the different groups (U/L, n=8, x±s).
| Group | AMY | ALT | AST |
|---|---|---|---|
| Control | 545.11±23.52 | 24.29±3.17 | 19.23±2.39 |
| AG490 | 558.22±31.76 | 28.36±6.25 | 21.28±3.74 |
| SAP-6 h | 1,247.45±156.37a | 156.64±17.48a | 276.39±27.44a |
| SAP-12 h | 3,478.26±212.58a | 198.49±21.36a | 396.45±30.27a |
| SAP-18 h | 4,461.64±346.17a | 352.23±29.18a | 478.46±31.57a |
| SAP-AG490-6 h | 1,582.16±125.34a | 117.56±16.37a,b | 324.36±23.78a,b |
| SAP-AG490-12 h | 3,201.56±199.29a | 155.82±24.56a,b | 320.69±29.74a,b |
| SAP-AG490-18 h | 3,719.74±287.63a,b | 287.33±19.63a,b | 386.48±28.83a,b |
No changes of AMY, ALT and AST were observed in the control and AG490 groups. Levels of AMY, ALT and AST increased significantly under SAP conditions. AG490 decreased the effects in SAP-AG490 groups. P>0.05 control vs. AG490 groups.
a
P<0.05 vs. control groups.
b
P<0.05 for multiple comparisons of SAP and treatment groups at the same time point. AMY, amylase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; SAP, severe acute pancreatitis.